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Abstract
Background: 9s-hydroxy-octadecadienoic acid (9S-HOD), one of the natural products of linoleic acid oxygenation
by 15-lipoxygenase (15-LOX), has been found to have anti-tumor properties in vitro and in vivo. The present study
therefore investigated whether 9S-HOD affects acute leukemia HL-60 cells.
Methods: The cytotoxicity of 9S-HOD in HL-60 with or without the presence of fetal bovine serum (FBS) in the
culture media was tested using cell viability assays and flow cytometry. To explore the mechanism of its anti-tumor
activity by 9S-HOD, we used a proteomic analysis to identify HL-60 cells protein profiles, based on two-dimensional
gel electrophoresis (2-DE) and mass spectrometry (MS) identification.
Results: 9S-HOD exerted cytotoxicity efficacy and induced apoptosis in HL-60 cells, and the cytotoxicity was largely
attenuated by the presence of FBS in culture media. The proteomic results revealed that 9S-HOD remarkably altered
the abundance of 23 proteins that were involved in mRNA metabolic process, protein binding, DNA replication and
apoptosis.
Conclusions: Our results indicated that 9S-HOD exerts cytotoxicity in HL-60 cells by affecting several pathways.
Keywords: 9s-hydroxy-octadecadienoic acid, Acute leukemia cells, Proteomics, Bioinformatics analysis
Background
Leukemia is one of the most common cancers in the
world, especially the type of acute myeloid leukemia
(AML). AML is characterized by the uncontrolled
growth of abnormal white blood cells in the bone mar-
row and interfere with the production of normal blood
cells [1]. Most current treatment strategies kill cancerous
cells by chemotherapeutic agents with a number of se-
vere toxic side-effects [2]. Therefore, the search for new
anti-leukemia treatments has increased and natural
products or their derivatives have been an important
source due to their diverse activities [3].
Naturally occurring oxylipins, known as oxidized metabo-
lites of long chain polyunsaturated fatty acids, have import-
ant roles in animals and plants for cell signaling and defense
in response to attack from microbes or pathogens [4]. The
hydroxyl-octadecadienoic acids (HODEs) are the major
reaction products of linoleic acid oxygenation by 15-
LOXenzyme, including 9-hydroxy-octadecadienoic acid
(9-HOD) and 13-hydroxy-octadecadienoic acid (13-
HOD) [5]. HODEs are well-known for its anti-
inflammatory properties, particularly in cardiovascular
and other inflammatory diseases [6]. Recently, studies
have demonstrated that HODEs are associated with a
number of cancers, revealing possible novel drugs for
chemoprevention and/or treatment of a number of
cancers prevention [7–9].
Multiple cellular and molecular mechanisms seem to
be involved in the anti-cancer effects of HODEs. Hampel
et al. [10] indicated that 9- and 13-HODE, as endogen-
ous fatty acid ligands for PPARγ, possess differential, lig-
and specific actions in monocytic cells to regulate cell
cycle progression, apoptosis and PPARγ2 gene expres-
sion. Interesting, recent studies show that (S)-HODE
decrease cell growth and DNA synthesis, and induce
apoptosis of Caco-2 cells, whereas (R)-HODE presents
the opposite action [11]. Therefore, the present study
considered whether 9S-HOD affects acute leukemia HL-
60 cells, and what is the mechanism? The aim of this
study was to investigate the effects of 9S-HOD on acute
leukemia HL-60 cells. Furthermore, 9S-HOD-treated
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HL-60 cells were analyzed by a 2D-gel based proteomics
approach and differentially expressed proteins were
identified by mass spectrometry. The integration of pro-
teomics and bioinformatics analyses revealed 9S-HOD
may affect several pathways.
Methods
Materials
HODs (≥98.0 %, HPLC) were purchased by Larodan
Fine Chemicals AB (Solna, Sweden), t10,c12-Conjugated
linoleic acid (t10,c12-CLA, ≥96.0 %, HPLC) were pur-
chased from Aldrich Chemical Co (Milwaukee, USA).
RPMI 1640, CD Hybridoma, AIM-V media, Apoptosis
Assay Kit#2 and Trizol LS were purchased from GIBCO
(Carlsbad, USA). All reagents for 2-D electrophoresis
were obtained from Amersham Pharmacia Biotech
(Uppsala, Sweden).
Cell culture and cell viability assay
HL-60 cells were obtained from the Chinese Academy of
Sciences Cell Bank. They were cultured in RPMI 1640
medium plus 10 % (v/v) FBS under standard culture
conditions. Prior to seeding cells to the microplates, cells
media were replaced with serum (FBS)-free/ (or serum)
culture media. Cells were then sub-cultured and treated
with drugs which were dissolved in ethanol at a range of
concentration (7.5 ~ 240 μM). After 24–48 h incubation,
CCK-8 (20 μL) was added of to each well and incubated
for 3 h. The final concentration of ethanol was <0.2 %
(v/v). Cell viability was measured using a microplate
reader (Polarstar, BMG Labtechnologies) at a wavelength
of 490 nm. The effects of the drugs were expressed as
percentage of cell viability against concentrations of
drugs. Each performed in triplicate for three times.
Apoptosis assay and DAPI staining
For DAPI (4′,6-Diamidino-2-Phenylindole, Dihydrochlor-
ide) staining, HL-60 cells were incubated with 9S-HOD for
48 h. The cells were collected and incubated in 0.1 mol/L
PBS (pH = 7.4) containing 50 μg/ml DAPI and 100 μg/ml
DNase-free RNase A at 37 °C for 20 min. Apoptotic cells
were identified as typical morphology of shrinkage of the
cytoplasm, membrane blebbing, and nuclear condensation
and/or fragmentation. For flow cytometry analysis, cells
treated with vehicle and 9S-HOD for 0–48 h were collected
and stained with Annexin V-FITC and propidium iodide
(PI) according to the manufacturer’s protocol and analyzed
by flow cytometry, followed by data analysis using Cell
Quest v.3.1 Software (Becton Dickinson, USA).
Protein separation by 2-DE
HL-60 cells were cultured in RPMI 1640 media with or
without 9S-HOD (20 μM) for 48 h. To perform 2-DE,
the cells were dissolved in lysis buffer (7 M urea, 4 %
CHAPS, 40 mM Tris, 65 mM DTT). Samples were soni-
cated on ice for 10 s with an ultrasonic processor and
centrifuged for 1 h at 40,000 × g at 4 °C. Protein concen-
tration was measured by the method of Bradford with
bovine serum albumin used as the standard. Proteins
(120 μg) were resuspended with 300 μl of IEF rehydra-
tion buffer (7 M urea, 2 M thiourea, 2 % CHAPS, 2 mM
TBP, 0.3 % carrier ampholytes pH 3–10, and 0.002 %
bromophenol blue). After sample loading, IEF gels were
run at 250 V for 1 h, 500 V for 1 h, 1000 V for 1 h,
10,000 V for 3 h, 10,000 V for 65,000 V.h. After IEF, IPG
strips were processed to reduction and alkylation in two
equilibration steps. Strips were first equilibrated for
15 min in 6 ml of equilibration buffer I (1.5 M Tris
pH 8.8, 6 M urea, 20 % glycerol, 1 % SDS, and 2 %
DTT) and then equilibrated for 15 min in equilibration
buffer II (1.5 M Tris pH 8.8, 6 M urea, 20 % glycerol, 1 %
SDS, and 2.5 % iodoacetamide). The second dimension
separation was performed with 12.5 % SDS-PAGE in Pro-
tean II xicell (Bio-Rad) and run at 10 mA for 1 h and then
28 mA for 9.5 h at 16 °C, until the dye front reached the
gel border. The analytical gels were visualized with silver
staining method that was mass spectrometry compatible
[12]. After that, the digitalized gel images were analyzed
(spot detection, count and map matching) were performed
using PDquest 8.0.1 software (Bio-Rad).
In-Gel digestion and identification
In-gel digestion was performed according to the method
described by Rosenfeld [12]. The stained protein spots
were excised from the gel and digested. The gel pieces
were rinsed three times and spots were extracted with
25 mM NH4HCO3 and 50 % acetonitrile, and then dried
completely. The dried gels were rehydrated in a digestion
buffer of 25 mM NH4HCO3 containing 10 ng/μl modified
trypsin. The gel slices were completely covered by the di-
gestion buffer and left to incubate overnight at 37 °C.
MS identification and database search
Peptide mixtures of each gel spot were dissolved in
0.1 % TFA, desalted, and concentrated. The sample was
mixed with the same volume of matrix (CHCA in 30 %
ACN/0.1 % TFA), spotted on a target disk, and allowed
to air-dry. The peptides were analyzed using a Bruker
ultrafleXtreme MALDI-TOF mass spectrometer (Bruker
Daltonics, Germany). The peptide sequence was deter-
mined with MASCOT software. The search was based
on the NCBI protein database on the assumption that
peptides aremonoisotopic, oxidized at methionine resi-
dues, and carbamidomethylated at cysteine residues.
Mass tolerance was allowed within 150 parts/million
(ppm). Proteins matching more than five peptides and
with a MASCOT score higher than 60 were considered
significant (P < 0.05).
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Statistical analysis
Each assay was repeated for three times. Values were
expressed as mean ± SD. Student’s t-test were used for
evaluate the statistical significant differences in groups.
One-way ANOVA was used to assess the differences be-
tween the vol % values (fold changes of spot volume) of
each identified protein. GraphPad Prism 5 was used and
P value of < 0.05 was considered statistically significant
differences.
Results
The effect of FBS content in culture medium on
cytotoxicity of 9S-HOD
The cytotoxicity of 9S-HOD in HL-60 cell was assayed
by CCK-8 (Fig. 1). HL-60 cell were cultured with RPMI
supplemented with 5 % FBS (+FBS), RPMI without FBS
(−FBS), serum-free medium CD or AIM-V for 24–72 h.
The cell viability at 24 h was markedly inhibited by 9S-
HOD when cultured with CD, while 9S-HOD did not
show this effect in other media (Fig. 1a). The cytotox-
icity of 9S-HOD cultured in + FBS or CD media for 48 h
were significantly higher than that for 24 h culture
(Fig. 1b). Compared the cell viability rate in + FBS with
CD media for 24 and 48 h, the cytotoxicity effect of 9S-
HOD was largely attenuated by the presence of FBS in
culture medium. The cell viability rate by of 9S-HOD
was 49.9 % for 72 h when cultured with 5 % FBS (data
not shown). However, 9S-HOD did not show cytotox-
icity in –FBS or AIM-V media.
HL-60 cells were cultured in + FBS, −FBS or CD media
to test cell growth (Fig. 1c). With + FBS in culture
medium, the cell viability rate was used as control
(100 %). There was no significant difference in the cell
viability rate between + FBS and CD for 24 and 48 h
(P > 0.05, but sharply decreased to 27.2 % for 72 h in CD
culture medium (P < 0.05). Meanwhile, there was signifi-
cant difference in the cell viability rate between + FBS
and –FBS (P < 0.05). In FBS-free culture medium, the
cell viability rates were 49.7, 30.9 and 22.4 % for 24, 48
and 72 h, respectively.
When cultured in CD medium for 48 h in the pres-
ence of 9S-HOD or 10 t,12c-CLA shown concentration-
dependant cytotoxicity by the reduction of CCK-8
(Fig. 1d). 10 t,12c-CLA started to show noticeable activ-
ity at 240 μM while 9S-HOD shown significant cytotox-
icity effect from 7.5 to 60 μM (P < 0.05).
To determine whether the cytotoxicity effect was
caused by cell apoptosis, HL-60 cells were treated with
20 μM of 9S-HOD for 48 h and DAPI staining was per-
formed. Treated cells showed marked nuclear fragmen-
tation and chromatin condensation which were clear
indications of apoptosis (Fig. 2b), while control cells
showed intact cell bodies with clear round nuclei
(Fig. 2a). Meanwhile, we found a time-dependent increase
Fig. 1 The cell viability of HL-60 cell treated with/without 9S-HOD in different culture media. a Effects of 9S-HOD for 24 h in + FBS, −FBS, CD and
AIM-V media. b Effects of 9S-HOD for 48 h in + FBS, −FBS, CD and AIM-V media. c The cell viability of HL-60 cell for 24 ~ 72 h in + FBS, −FBS and
CD media. d Effects of 9S-HOD or 10 t,12c-CLA for 48 h in CD medium. B: blank; V: vehicle; HOD: 9S-HOD; +FBS: RPMI medium containing 5 %
FBS; −FBS: RPMI medium without FBS (serum free); CD: CD hybridoma medium (serum free); AIM-V: AIM-V medium (serum free).
**P < 0.01, ***P < 0.001
Li et al. Lipids in Health and Disease  (2016) 15:192 Page 3 of 8
in cell apoptosis (FITC-Annexin-V and PI double-positive
cells) for 0–24 h after treated with 9S-HOD (P < 0.05),
then the percentage of apoptosis cell was decreased from
24 to 48 h due to the late apoptosis cell increasing (Fig. 2c).
Our data suggest that the cytotoxicity effect of 9S-HOD
may be associated with an increase in cell apoptosis.
Proteomic results and statistical analysis
To investigate the mechanism, the protein expression
changes upon 9S-HOD treatment in HL-60 cells were
analyzed by 2-DE-based proteomics approach. After
20 μM 9S-HOD or vehicle treatment for 24 h, protein
lysates were prepared and separated first by IEF followed
by SDS-PAGE separation; and the resulting 2-DE gel
were stained with collocidal coomassie blue silver. Then
the stained 2D-gel were scanned and analyzed by GE
software, 3-fold differentially expressed proteins were ex-
cised and processed for further MS analysis. In Fig. 3,
representative 2-DE gels of untreated (a) and 9S-HOD
treated HL-60 cell (b) are shown. As a result, the 2-DE
gel showed an obvious separation of cell proteins, which
1200 protein spots were detected in each gel. Comparing
the spots of untreated and 9S-HOD treated HL-60 cell
by PDquest software for image analysis, a total of 32
protein spots exhibited 3-fold significant difference
(P < 0.05). Among the 32 proteins, 20 peptide mass
fingerprints (PMFs) were matched identified by
MALDI-TOF-MS and protein database searching, as
displayed in Table 1.
Bioinformatic analysis
We analyzed the GO enrichment of fourteen up-regulated
and six down-regulated proteins in 9S-HOD treated HL-
60 cells (Table 1) by using the http://genecodis.cnb.csic.es/
website. These dysregulated proteins were categorized
into different biology processes including response to
mRNA metabolic process, protein binding, DNA replica-
tion and apoptosis (Fig. 4a). STRING software was used to
map a network of interacting proteins whose levels chan-
ged following 9S-HOD treatment.
Discussion
It is reported that HODs showed more potent anti-
tumor activities than lead compound CLA, especially
(S)-HOD had more activity compared with the corre-
sponding (R)-HOD [11, 13]. To date, the mechanism of
9-HOD involved of inhibiting cell proliferation and indu-
cing apoptosis. In this study, we also observed cytotoxicity
and apoptosis in HL-60 cells after treatment of 9S-HOD,
observing typical morphological changes such as chroma-
tin condensation and fragmentation. Furthermore, the 9S-
HOD anti-tumor activity on HL-60 cell was severely de-
layed and attenuated by the presence of FBS in culture
medium, which was correspond well to our previous find-
ing on other cancer cells [14]. This may be due to serum
Fig. 2 9S-HOD induces HL-60 cell apoptosis. Morphological analysis of HL-60 cell after a vehicle or b 20 μM 9S-HOD treatment for 48 h, and c
apoptosis examined using Annexin V/PI staining and flow cytometry. *P < 0.05, ***P < 0.001
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Fig. 3 Two-DE profiles of a vehicle or b 20 μM 9S-HOD treatment of HL-60 for 48 h. Total protein exacts were separated on pH 3–10, 17 cm IPG
strips and stained with silver. MS-based identification of these spots is summarized in Table 1
Table 1 The identification of protein spots on 2-DE
Spot Accession Protein name Gene M.W. pI Score
mRNA metabolic process
13 Q69YN4 Protein virilizer homolog↓ KIAA1429 202584.08 4.44 66.6
9 Q13185 Chromobox protein homolog 3↓ CBX3 20969.41 4.96 84.6
22 P61978 Heterogeneous nuclear ribonucleoprotein K↑ HNRNPK 48760.25 5.17 54.5
Protein binding
32 P60709 Actin, cytoplasmic 1 ↑ ACTB 42051.86 5.15 122
23 P05388 60S acidic ribosomal protein P0↑ RPLP0 34388.88 5.77 170
29 P11171 Protein 4.1↑ EPB41 81755.32 5.54 61
6 Q6PK50 HSP90AB1 protein↓ HSP90AB1 40270.42 4.61 78.6
DNA replication
1 Q01105 Protein SET↓ SET 30974.22 3.86 98
2 Q01105 Protein SET↓ SET 31310.48 3.83 202
5 P12004 Proliferating cell nuclear antigen↓ PCNA 29092.42 4.31 94.1
Cytoskeleton
21 P63261 Actin, cytoplasmic 2 ↑ ACTG1 42107.92 5.16 321
17 I3L1U9 Actin, cytoplasmic 2, N-terminally processed↑ ACTG1 23886.98 5.11 129
Apoptosis process
26 P51878 Caspase-5↑ CASP5 33966.33 8.55 60.4
Negative regulation of myeloid cell differentiation
4 E9PKG1 Protein arginine N-methyltransferase 1↓ PRMT1 38198.03 6.06 106
Unknown
8 P35527 Keratin, type I cytoskeletal 9↓ KRT9 62254.9 4.89 67.1
31 Q15195 Plasminogen-like protein A↑ PLGLA 11135.6 6.5 63.6
28 Q8IUZ0 Isoform 3 of Leucine-rich repeat-containing protein↑ LRRC49 74491.59 7.15 60
27 B4DVQ0 cDNA FLJ58286, highly similar to Actin, cytoplasmic 2↑ 37666.76 5.45 147
20 B4E335 cDNA FLJ52842, highly similar to Actin, cytoplasmic 1↑ 39542.66 5.28 207
19 B4DW52 cDNA FLJ55253, highly similar to Actin, cytoplasmic 1↑ 38950.3 5 148
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albumin in culture medium could strongly bind to fatty
acid [11]. Interestingly, in the present study, CD media
(serum-free) were demonstration to increase the antitu-
mor activity of 9S-HOD, whereas the activity were weak
in –FBS and AIM V media (also serum-free). This may be
due to the HL-60 cells grew not well in –FBS media with
the cell viability of 49.7 % for 24 h, 30.9 % for 48 h com-
pared to that in FBS media as 100 %.
Our proteomic study revealed differences between
control and 9S-HOD treated group. 33 differentially ex-
pression proteins were found, 19 of which were success-
fully identified by mass spectrometry followed by NCBI
database. Functional annotation analysis showed that the
differential proteins were involved in various biological
processes such as mRNA metabolic process, protein
binding, DNA replication, response to calcium ion,
apoptosis and negative regulation of myeloid cell
differentiation.
In order to better understand the mechanisms of 9S-
HOD in HL-60, the interaction network of proteins was
built by the STRING as described previously shown as
Fig. 4b. Most of the proteins in the map have direct or
indirect links, in which protein ACTB, EPB41,
HSP90AB1 and RPLP0 functioning in protein folding
Fig. 4 Distribution of GO annotations of biological functions for identified proteins. a Multi-level pie chart of combined graph of GO biological
functions annotations by Genecodis2; b The network of proteins was generated by STRING
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and processing form a small close network, suggesting
that 9S-HOD may regulate this pathway. Among these
proteins, hot shock protein 90 (Hsp90) is associated with
tumorigenesis. The availability of drugs that can specific-
ally target Hsp90 and inhibit its function, resulting in
the depletion of client proteins, has made Hsp90 a novel
and exciting target for the development of anti-tumor
drugs [15]. Hsp90 has two main isoforms, namely,
Hsp90-alpha (Hsp90AA1) and Hsp90-beta (Hsp90AB1)
[16]. A study of various tumor cell lines revealed that
Hsp90-beta was up-regulated expression in A549, H520,
H446 and HL-60 cell lines [17]. In our results, we de-
tected the remarkably 4-fold down-regulated expression
of Hsp90AB1 in the 9S-HOD treated group, implicating
that 9S-HOD may affect on the protein folding and thus
inhibited cell proliferation. Meanwhile, EPB41 with func-
tioning in positive regulation of protein binding was up-
regulated by 9S-HOD treatment.
On 2-DE, PCNA is usually detected as a single spot, as
previously described [18]. The exactly PCNA theoretical
parameters is pI ~4.57 and mass ~30 kDa on the 2-DE
map. The PCNA spot in this study corresponded to a
polypeptide of pI 4.31 and mass 29 kDa, showing that
the PCNA is not post-translational modified [19]. It is
also interesting to note that PNCA protein was the core
node associated with many other proteins in the network.
PCNA is the key cell cycle marker protein, involving in
DNA replication, DNA repair, chromatin remodeling and
epigenetics [20, 21]. Interaction with different protein
partners is an important regulatory mechanism for the di-
verse functions of PCNA. Since more than 100 PCNA-
interacting proteins and several PCNA modifications have
already been reported [22]. Among the proteins involved
in protein processing, EPB41 and Hsp90AB1 were inter-
active with PCNA in this study, which also has been veri-
fied previously [23, 24]. It is reported that PCNA was one
of the Hsp90 client proteins in HCT-116 [24], suggesting
that the association of PCNA with Hsp90 might be a gen-
eral phenomenon in cancer cells. The same phenomenon
was found in our results that Hsp90AB1 and PCNA pro-
tein were down-regulated by 9S-HOD in HL-60.
Another interesting protein is the 60s acidic ribosomal
protein p0 (RPLP0), which belongs to the L10P family of
ribosomal proteins. Proteomic profiling pointed to an as-
sociation between RPLP0 up-regulation and cancer in
several tumor cells [25], which is involved in mRNA
translation. In addition, a recent report showed that
RPLP0 was up-regulated in patients with the most com-
mon types of cancer, indicating that the expression level
of RPLP0 could be useful as a prognostic marker in tu-
mors [26]. In our study, 9S-HOD caused down-
regulated of RPLP0 protein in HL-60 cells.
Three proteins had been demonstrated to be related
with mRNA metabolic process, including KIAA1429,
CBX3 and hnRNPK. RNA process is important for the
proliferation of tumor cells and RNAi knock-down of
RNA processing proteins in cancer cells induces apop-
tosis [27]. In agreement with these findings, the protein
hnRNPK was significantly down-regulated by 9S-HOD.
hnRNPK is a nucleic acid-binding protein that serves as
a docking platform integrating transduction pathways to
nucleic acid-directed processes [28]. Knock-down of
hnRNPK results in strongly reduced migratory activity
of cancer cells, strongly suggesting hnRNPK as a prom-
ising target molecule for cancer progression [29].
Conclusion
In conclusion, 9S-HOD exerted cytotoxicity efficacy and
induced apoptosis in HL-60 cells, and the cytotoxicity
was largely attenuated by the presence of FBS in culture
media. A classical proteomic approach is performed to
elucidate the mechanism of its anti-leukemia activity by
9S-HOD. Based on 2-DE and MALDI-TOF-MS, 23 dif-
ferentially expressed proteins were identified. Bioinfor-
matics analysis on the proteomic alterations suggested
that 9S-HOD may affect several pathways such as
mRNA metabolic process, protein binding, DNA repli-
cation and apoptosis. However, further studies would
be necessary to clarify the exact targets by 9S-HOD in
treating leukemia.
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